News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Havix was incorporated under the laws of the State of Delaware on February 17, 2015
Subscribe To Our Newsletter & Stay Updated
